For patients 6 years and older with ADHD
DYANAVEL XR Tablet Starts as an IR
and Lasts as an ER1
After initial peak, LiquiXR® technology allows for a gradual decline in drug levels to avoid sudden drop-offs throughout the day1
Mean Plasma d- and l-Amphetamine Concentration-Time Profiles for DYANAVEL XR Tablet and Oral Suspension1
Will not disrupt your patients’ morning routines—DYANAVEL XR tablet
and oral suspension can be taken with or without food
Study Details: Following a single, 20-mg oral dose of DYANAVEL XR (amphetamine) tablet given to 36 healthy adults in a 4-period, 4-treatment, 4-sequence crossover study, exposures (Cmax and AUC) to d- and l-amphetamine were similar to administration of an equal dose of DYANAVEL XR oral suspension. Peak plasma concentration (Tmax) for d- and l-amphetamine occurred at a median time of 5.0 hours after dosing. The relative bioavailability of DYANAVEL XR tablet compared with an equal dose of DYANAVEL XR oral suspension, for d- and l-amphetamine, was 105% and 106%, respectively. Exposures (Cmax and AUC) to d- and l-amphetamine for DYANAVEL XR tablet swallowed whole were similar to those when the tablet was chewed and were similar under fed and fasting conditions.1
AUC, area under the curve; Cmax, peak concentration; Tmax, time to maximum concentration.
Reference: 1. Pardo A, Kando JC, King TR, Rafla E, Herman BK. CNS Spectr. 2020;25(6):774-781.